ABSTRACT
Trade name: Tykerb (GSK) Indications: Breast cancer Category: Epidermal growth factor receptor (EGFR); Tyrosine kinase inhibitor Half-life: 24 Hours Clinically important, potentially hazardous interactions with: atazanavir, carbamazepine, clarithromycin, CYP3A4 inhibitors, dexamethasone, grapefruit juice, indinavir, itraconazole, nefazodone, nelfinavir, phenobarbital, phenytoin, rifabutin, rifampin, rifapentin, ritonavir, saquinavir, St John’s wort, telithromycin, voriconazole. The concomitant use of strong CYP3A4 inducers should be avoided
